Medtronic study to assess dual antiplatelet therapy in Resolute Onyx patients

Medtronic has announced the launch of a new global randomised clinical trial that aims to answer critical unanswered questions in interventional cardiology.

The trial will evaluate one-month dual antiplatelet therapy (DAPT), which combines aspirin and an anti-clotting medication, among patients implanted with the Resolute Onyx drug-eluting stent during percutaneous coronary intervention.

The aim of this study will be to inform DAPT guidelines for newer-generation stent recipients, with current guidance favouring bare-metal stents in patients with stable ischaemic heart disease who might require a shorter dual antiplatelet regimen.

Up to around 2,000 patients will be enrolled at approximately 70 sites worldwide.

Dr Martin Rothman, vice-president for medical affairs at Medtronic's coronary and structural heart division, said: "We're continuously looking at ways to invest in clinical evidence and expand our product portfolio to help address the most important unanswered questions and unmet needs in interventional cardiology."

Resolute Onyx received European CE Mark approval in September 2014, before being ratified by US regulators in April this year.

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.